Lecornu Marie, Lesueur Paul, Salleron Julia, Balosso Jacques, Stefan Dinu, Kao William, Plouhinec Tiphaine, Vela Anthony, Dutheil Pauline, Bouter Jordan, Marty Pierre-Alban, Thariat Juliette, Quintyn Jean-Claude
Radiation Oncology Department, Centre François Baclesse, Caen, France.
Radiation Oncology Department, Centre Guillaume le Conquérant, Caen, France.
Front Oncol. 2021 Jun 15;11:673886. doi: 10.3389/fonc.2021.673886. eCollection 2021.
Proton therapy (PT) can be a good option to achieve tumor control while reducing the probability of radiation induced toxicities compared to X-ray-based radiotherapy. However, there are still uncertainties about the effects of PT on the organs in direct contact with the irradiated volume. The aim of this prospective series was to report 6-month follow-up of clinical and functional optic neuropathy rates of patients treated by proton therapy using a standardized comprehensive optic examination.
Standardized ophthalmological examinations were performed to analyze subclinical anomalies in a systematic way before treatment and 6 months after the end of proton therapy with: Automatic visual field, Visual evoked potential (VEP) and optic coherence of tomography (OCT).
From October 2018 to July 2020 we analyzed 81 eyes. No significant differences were found in the analysis of the clinical examination of visual functions by the radiation oncologist. However, considering VEP, the impairment was statistically significant for both fibers explored at 30'angle (p:0.007) and 60'angle (p <0.001). In patients with toxicity, the distance of the target volume from the optical pathways was more important with a p-value for 30'VEP at 0.035 and for 60'VEP at 0.039.
These results confirm uncertainties concerning relative biological effectiveness of proton therapy, linear energy transfer appears to be more inhomogeneous especially in areas close to the target volumes. The follow-up of patients after proton therapy is not an easy process to set up but it is necessary to improve our knowledges about the biological effects of proton therapy in real life. Our study which will continue during the coming years, suggests that follow-up with in-depth examinations such as VEP as a biomarker could improve the detection of early abnormalities.
与基于X射线的放射疗法相比,质子治疗(PT)可能是实现肿瘤控制同时降低放射诱导毒性概率的良好选择。然而,PT对与照射体积直接接触的器官的影响仍存在不确定性。本前瞻性系列研究的目的是报告使用标准化综合眼科检查对接受质子治疗的患者进行6个月随访的临床和功能性视神经病变发生率。
在质子治疗结束前和结束后6个月进行标准化眼科检查,以系统分析亚临床异常情况,检查项目包括:自动视野检查、视觉诱发电位(VEP)和光学相干断层扫描(OCT)。
2018年10月至2020年7月,我们分析了81只眼睛。放射肿瘤学家对视觉功能进行的临床检查分析未发现显著差异。然而,考虑VEP,在30°角(p:0.007)和60°角(p<0.001)探测的两种纤维的损伤在统计学上均具有显著性。在有毒性的患者中,靶体积与视路的距离更为重要,30°VEP的p值为0.035,60°VEP的p值为0.039。
这些结果证实了质子治疗相对生物效应的不确定性,线性能量传递似乎更不均匀,尤其是在靠近靶体积的区域。质子治疗后对患者进行随访并非易事,但有必要提高我们对质子治疗在现实生活中生物效应的认识。我们将在未来几年继续进行的研究表明,以VEP等深入检查作为生物标志物进行随访可以改善早期异常的检测。